4Cappuzzo F,,Ciuleanu T,Stelmakh L,et al.Erlotinib as maintenance treatment in advanced non-small-cell lung cancer:a multicentre,randomised,placebo-controlled phase3study. Lanct Oncol . 2010
5Gandara D,Kim ES,Herbst RS,et al.Carboplatin,paclitaxel,cetuximab,and bevacizumab followed by cetuximab and bevacizumab maintenance in advancednon-small cell lung cancer(NSCLC):A SWOG phase II study. Journal of Clinical Oncology . 2009
6Miller VA,O’Connor P,Soh C,et al.A randomized,double-blind,placebo-controlled,phase IIIb trial(ATIAs)comparing bevacizumab(B)thempy with or without edotinib(E)after completion of chemotherapy with B for first,line treatment of locally advanced,recurrent,or metastatic non-small cell lung. ASCO Annual Meeting . 2009
7Dong B,Zhu YM.Molecular-targeted therapy for cancer. Chinese Journal of Cancer Research . 2010
8Ramalingam S,Belani CP.Molecularly-targeted therapies for non-small cell lung cancer. Expert Opinion on Pharmacotherapy . 2005
9Grossi F,,Aita M,Foilador A,et al.Sequential,alternating,and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer:a review for the literature. The Oncologist . 2007
10Brodowicz T,Krzakowski M,Zwi er M,et al.Cispatin and gemcitabine frist-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer:A phase III trial. Lung Cancer . 2006
2Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.J Clin Oncol, 2000.18(12): 2354-2362.
3Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-ceU lung cancer previously treated with platinum-based chemotherapy. Clin Oncol, 2000,18(10): 2095-2103.
4Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 2004, 22(9): 1589-1597.
5NSCLC Meta-Analyses Collaborative Group. Chemotherapyin addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controUed trials. J Clin Oncol, 2008, 26(28): 4617-4625.
6Carney DN. Lung cancer-time to move on from chemotherapy. New EnglJ Med, 2002, 346(2): 126-128.
7Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2009, 59(4): 225-249.
8Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000, 103(2): 211-225.
9Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. New EnglJ Med, 2008, 358(11): 1160-1174.
10Shepherd FA, Rodrigues PJ, Ciuleanu T, et al Erlotinib in previously treated non-small-cell lung cancer. N EnglJ Med, 2005, 353(2): 123-132.
